Allergan's cash-use plan, pipeline could add to share run

By Lewis Krauskopf NEW YORK (Reuters) - Four months after the collapse of its deal to be bought by Pfizer , Allergan plc has a $33 billion war chest, a pipeline of experimental drugs that some investors view as undervalued and optimistic shareholders scooping up its shares. Wall Street could get a glimpse of Allergan's plans when it reports second-quarter results on Monday.